CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $64.73M, above the global median of $18.73M
- FinancialsAltman Z-Score 1.71: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.89BCNY430.44M · vs all stocks (USD)
Revenue (TTM)
1.69BCNY251.55M · vs all stocks (USD)
Profit Margin
-41.65%vs Medical Devices peers
Beta
0.2680xvs all stocks
52-Week Change
-13.02%vs all stocks
Market Capitalization
2.89BCNY430.44M · vs all stocks (USD)
Enterprise Value
2.95BCNY439.47M · vs all stocks (USD)
Forward P/E
10.41xvs Medical Devices peers
Price to Sales (TTM)
1.71xvs Medical Devices peers
Price to Book (MRQ)
1.15xvs Medical Devices peers
Enterprise to Revenue
1.75xvs Medical Devices peers
Enterprise to EBITDA
-6.64xvs Medical Devices peers
Gross Margin
36.65%vs Medical Devices peers
Profit Margin
-41.65%vs Medical Devices peers
Operating Margin
-9.16%vs Medical Devices peers
Return on Assets (TTM)
-8.21%vs Medical Devices peers
Return on Equity (TTM)
-24.52%vs Medical Devices peers
Revenue (TTM)
1.69BCNY251.55M · vs all stocks (USD)
Revenue per Share (TTM)
3.28CNYUpdated Sep 19, 2026Quarterly Revenue Growth
9.10%vs Medical Devices peers
Gross Profit (TTM)
411.76MCNY61.42M · vs all stocks (USD)
EBITDA (TTM)
-443.44MCNY-66.14M · vs all stocks (USD)
Net Income (TTM)
-702.46MCNY-104.78M · vs all stocks (USD)
Operating Cash Flow (TTM)
18.99MCNY2.83M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
433.96MCNY64.73M · vs all stocks (USD)
5-Year Average Dividend Yield
2.11%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
471.64MCNYFY2025 · Dec 31, 2025Revenue
1.64BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.07BCNYFY2025 · Dec 31, 2025Gross Profit
576.20MCNYFY2025 · Dec 31, 2025Operating Income
-337.58MCNY-50.35M · vs all stocks (USD)
Pre-tax Income
-812.11MCNYFY2025 · Dec 31, 2025Income Tax Expense
72.68MCNYFY2025 · Dec 31, 2025Net Income
-884.79MCNYFY2025 · Dec 31, 2025EBIT
-788.79MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-95.37MCNYFY2025 · Dec 31, 2025Research & Development
189.62MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
302.28MCNYFY2025 · Dec 31, 2025Other Operating Expenses
10.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
6.45MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
23.32MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.42CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.42CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
514.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
514.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-884.79MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
152.65MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-713.02MCNYFY2025 · Dec 31, 2025Free Cash Flow
-844.21MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
853.17MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-884.79MCNYFY2025 · Dec 31, 2025Other Non-cash Items
42.11MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
76.36MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
53.31MCNYFY2025 · Dec 31, 2025Capital Expenditures
-131.19MCNYFY2025 · Dec 31, 2025Net Acquisitions
1.50MCNYFY2025 · Dec 31, 2025Purchase of Investments
-60.00MCNYFY2025 · Dec 31, 2025Sale of Investments
2.04MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-187.66MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
611.92MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-403.32MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-15.45MCNYFY2025 · Dec 31, 2025Other Financing Charges
14.32MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
207.48MCNYFY2025 · Dec 31, 2025Shares Outstanding
514.36MSharesUpdated Sep 19, 2026Float Shares
391.45MSharesUpdated Sep 19, 2026% Held by Insiders
23.72%vs all stocks
% Held by Institutions
2.01%vs all stocks
Total Cash (MRQ)
831.08MCNY123.96M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.66CNYUpdated Sep 19, 2026Total Debt (MRQ)
491.14MCNY73.26M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1643xvs Medical Devices peers
Current Ratio (MRQ)
1.74xvs Medical Devices peers
Book Value per Share (MRQ)
4.89CNYUpdated Sep 19, 2026Total Assets
4.64BCNY692.32M · vs all stocks (USD)
Total Current Assets
2.41BCNYFY2025 · Dec 31, 2025Total Liabilities
1.53BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.23BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
179.24MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.35BCNYFY2025 · Dec 31, 2025Cash
853.12MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.80MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
857.93MCNYFY2025 · Dec 31, 2025Other Short-term Investments
60.36MCNYFY2025 · Dec 31, 2025Accounts Receivable
596.74MCNYFY2025 · Dec 31, 2025Inventory
643.51MCNYFY2025 · Dec 31, 2025Accounts Payable
319.40MCNYFY2025 · Dec 31, 2025Short-term Debt
618.13MCNYFY2025 · Dec 31, 2025Other Current Liabilities
44.80MCNYFY2025 · Dec 31, 2025Long-term Debt
80.58MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
60.81MCNYFY2025 · Dec 31, 2025Common Stock (Book)
514.35MCNYFY2025 · Dec 31, 2025Retained Earnings
1.71BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.11BCNY463.82M · vs all stocks (USD)
Treasury Stock
101.02MCNYFY2025 · Dec 31, 202552-Week Low
4.47CNYUpdated Sep 19, 202652-Week High
7.54CNYUpdated Sep 19, 202652-Week Change
-13.02%vs all stocks
Beta
0.2680xvs all stocks
50-Day MA
5.40CNYUpdated Sep 19, 2026200-Day MA
5.72CNYUpdated Sep 19, 2026Avg 10-Day Volume
4.65MSharesUpdated Sep 19, 2026Avg 30-Day Volume
7.21MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
-1.37CNYUpdated Sep 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.71: grey zoneSignificant
Altman Z-Score: 1.71
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $64.73M, above the global median of $18.73MNotable
Levered free cash flow (USD): 64,729,330.406Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
DiaMedica Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hua Medicine Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Skyworks Solutions Inc.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
Forward Industries, Inc.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease
Maccura Biotechnology Co., Ltd.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease